Navigation Links
Gene Network Sciences Names New CSO and Announces New Scientific Advisory Board
Date:4/16/2008

CAMBRIDGE, Mass., April 16 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced the creation of the new position of Chief Scientific Officer and a newly constituted Scientific Advisory Board (SAB) of world class experts from both the biopharmaceutical industry and leading academic organizations.

GNS's first Chief Scientific Officer, Dr. James Collins, is Professor of Biomedical Engineering and University Professor at Boston University and co-director of Boston University's Center for Biodynamics. Collins is a MacArthur Fellow, an original Technology Review TR100 award recipient, a recipient of an NIH Director's Pioneer Award, and a Rhodes Scholar. Professor Collins will also co-chair GNS's Scientific Advisory Board. He is the founder and former CSO of Cellicon Biotechnologies, a leading systems biology company, and Afferent Corporation, a medical device company.

"Professor Collins' broad experience as a scientific leader in systems biology and the reverse-engineering of genetic networks makes him uniquely qualified to lead GNS's scientific efforts," said Colin Hill, President and Chief Executive Office of GNS.

"During the past year, GNS has made important advances in the validation of its technology," said Collins. "In addition to discovering drug mechanism of action and biomarkers used by its pharma partners in clinical development, GNS's formation of discovery alliances with leading academic clinics and its discovery of potential therapeutic targets ab initio from human data has established GNS as a unique computational biology company."

Supporting Collins in his new role as CSO of GNS is a newly constituted Scientific Advisory Board that brings expertise in key areas that will be invaluable in evolving GNS's discovery engine and advancing GNS's pipeline of gene network based targets and diagnostics programs from discovery to market. Members of the new SAB are leading pharmaceutical executives and academic systems bi
'/>"/>

SOURCE Gene Network Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
2. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
3. ThirdBiotech Networking Group Launches
4. Social Network for Scientists Marks Ten Years Online
5. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
6. CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care
7. The Food Allergy & Anaphylaxis Network (FAAN) and Verus Pharmaceuticals Work Together to Raise Awareness of Food Allergies
8. Salugen to Present at Nutrition Capital Networks First In-Person Investor Meeting
9. Michigan Life Science Network to Form Two New Virtual Companies
10. CompareNetworks Media Group Delivers CME/CE Through Acuity Medical Education
11. Michigan Life Science Network: Virtual Companies Get Global Reception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)NEW YORK, Dec. 4 Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chroni
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
Breaking Biology News(10 mins):Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Research is vital to a cleaner, greener, low carbon future 2CCNY professor foresees rising Antarctic snowmelt 2Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 55997 1Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 55997 2Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 55997 3MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 1MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 2MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 3Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 1Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 2Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 3Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 4
X-GAL (5-Bromo-4-Chloro-3-Indolyl-Beta-D-Galactopyranoside), = 99.0% from AMRESCO, Inc.
Custom Peptide Synthesis from Raybiotech, Inc.
DTNB from Cayman Chemical
Keyhole Limpet Hemocyanin NP-KLH (Keyhole Limpet Hemocyanin), Unconjugated from Biosearch Technologies
Biology Products: